Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)22.90
  • Today's Change-0.25 / -1.08%
  • Shares traded2.45m
  • 1 Year change+49.67%
  • Beta2.9384
Data delayed at least 15 minutes, as of Apr 18 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.

  • Revenue in HKD (TTM)136.28m
  • Net income in HKD-913.85m
  • Incorporated2017
  • Employees432.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shandong Boan Biotechnology Co Ltd668.92m-129.19m5.17bn745.00--3.62--7.74-0.2537-0.25371.312.800.27321.352.53---5.28---7.02--66.16---19.31--0.8383-7.470.2352--19.80--64.02------
ImmuneOnco Biopharmaceuticls Shanghi Inc-100.00bn-100.00bn5.37bn---------------------------------------------------28.25--5.82------
Shanghai Fudan-Zhangjiang Bio-Pharm. Co920.63m117.55m6.18bn948.0018.290.8492--6.710.11430.11430.87592.460.29071.811.79971,129.103.717.034.649.0591.0692.1712.7517.263.62151.720.007339.16-17.502.78-21.28-0.632620.490.00
Tong Ren Tang Technologies Co Ltd7.33bn638.68m6.34bn4.03k9.930.85044.620.86490.49870.49875.725.820.52120.98355.68--7.647.6812.1012.3242.0443.5014.6516.112.37--0.144319.7913.046.011.25-2.73--0.0178
New Horizon Health Ltd1.47bn119.71m6.47bn1.04k59.032.0041.524.390.23950.23953.237.060.45362.162.081,678,685.003.67--3.99--88.74--8.10--10.50--0.1305--259.54--97.40------
Lepu Biopharma Co Ltd243.87m-23.91m6.97bn429.00--7.1886.8828.58-0.0144-0.01440.1470.58490.09171.061.62568,454.90-1.23---1.91--87.45---13.45--0.72010.13920.4549--1,347.16--96.79------
Everest Medicines Ltd136.28m-913.85m7.50bn432.00--1.39--55.07-2.92-2.920.435316.610.02032.254.57315,460.00-13.63-30.52-15.06-33.1472.67---670.57-5,745.258.29--0.0979--884.46---241.50--4.65--
Beijing Tong Ren Tang Chinese Medicine1.52bn540.39m7.56bn798.0013.991.9511.234.960.64560.64561.824.620.35220.64492.211,910,959.0013.6416.7115.5018.7568.6769.8838.7340.728.59--0.031740.80-11.910.1459-16.33-1.43--7.49
China Shineway Pharmaceutical Group Ltd4.89bn1.05bn7.69bn3.53k6.701.016.201.571.391.396.479.210.50731.446.31--10.898.0314.159.7775.1574.5521.4717.872.98--0.041145.7914.3211.9434.1413.89--12.88
Shanghai Henlius Biotech Inc5.84bn590.88m7.91bn3.64k13.393.348.081.361.091.0910.744.370.57311.959.101,605,213.005.80-8.5912.47-14.1472.6471.7710.12-27.370.37866.690.6512--67.82273.51178.53------
Cansino Biologics Inc373.54m-1.60bn8.27bn1.49k--0.7821--22.14-6.50-6.501.5123.070.03322.370.4626250,028.50-18.93-4.27-26.69-5.60-253.78---569.97-27.721.86--0.3381---66.52213.94-63.04--30.60--
Keymed Biosciences Inc383.19m-388.88m8.32bn897.00--2.55--21.72-1.49-1.491.4511.680.09060.731426.14427,188.20-9.16---10.05--89.59---101.04--9.18--0.123--253.87---16.63------
InnoCare Pharma Ltd799.22m-683.13m8.99bn1.07k--1.02--11.24-0.405-0.4050.47364.390.0731.393.39---6.38-13.41-8.08-15.3682.6185.99-87.42-172.164.13--0.1582--18.09240.3628.80------
Luye Pharma Group Ltd6.65bn576.36m9.93bn5.01k17.150.69117.401.490.1540.1541.783.820.2472.423.24--2.172.803.564.4568.4470.538.7810.391.212.680.3837--2.703.50-11.94-16.39----
AIM Vaccine Co Ltd1.29bn-1.41bn10.02bn1.62k--2.54--7.79-1.16-1.161.063.26------791,275.70--------75.88---164.24--0.7583-11.540.3158---6.06---307.07------
Data as of Apr 18 2024. Currency figures normalised to Everest Medicines Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

12.79%Per cent of shares held by top holders
HolderShares% Held
Janchor Partners Ltd.as of 30 Sep 202315.88m4.90%
RA Capital Management LPas of 23 Nov 202215.22m4.70%
The Vanguard Group, Inc.as of 05 Apr 20243.80m1.17%
BlackRock Fund Advisorsas of 04 Apr 20242.36m0.73%
Bosera Asset Management Co., Ltd.as of 31 Dec 20221.20m0.37%
Dimensional Fund Advisors LPas of 04 Apr 20241.06m0.33%
Wellington Management Co. LLPas of 27 Feb 2023678.30k0.21%
SSgA Funds Management, Inc.as of 04 Apr 2024476.50k0.15%
BlackRock Advisors (UK) Ltd.as of 02 Apr 2024440.50k0.14%
First Trust Advisors LPas of 05 Apr 2024326.79k0.10%
More ▼
Data from 13 Nov 2023 - 10 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.